U.S. markets closed
  • S&P Futures

    3,853.00
    +14.00 (+0.36%)
     
  • Dow Futures

    31,626.00
    +161.00 (+0.51%)
     
  • Nasdaq Futures

    12,665.00
    +1.25 (+0.01%)
     
  • Russell 2000 Futures

    2,211.10
    +21.40 (+0.98%)
     
  • Crude Oil

    67.42
    +1.33 (+2.01%)
     
  • Gold

    1,708.10
    +9.60 (+0.57%)
     
  • Silver

    25.72
    +0.43 (+1.71%)
     
  • EUR/USD

    1.1927
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3848
    +0.0020 (+0.14%)
     
  • USD/JPY

    108.4070
    +0.0250 (+0.02%)
     
  • BTC-USD

    51,648.25
    +2,571.20 (+5.24%)
     
  • CMC Crypto 200

    1,041.86
    +98.69 (+10.46%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    29,166.06
    +301.74 (+1.05%)
     

Liquidia to Report First Quarter 2020 Financial Results and Provide Corporate Update on May 11, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., May 06, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that first quarter 2020 financial results will be reported on Monday, May 11, 2020. The company will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and provide a corporate update.

The live call may be accessed by dialing 1-877-707-8711 (domestic) or 1-857-270-6219 (international) and entering the conference code: 1438598. A live and archived webcast of the call will also be available on the Events & Presentations page of the Liquidia website.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com